Loading…
Zhejiang pharma group selling probiotics, plant-based drugs and other OTC and prescription health products.
Zhejiang pharma group selling probiotics, plant-based drugs and other OTC and prescription health products.
In one line: A diversified Chinese Bayer Consumer Health.
Moat: narrow (brand, distribution). Established OTC and probiotic brands with broad pharmacy distribution across China.
Headquarters: Hangzhou, China · Employees: 7,826
Size Zhejiang CONBA Pharmaceutical (600572.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.56B, the 1578th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.26 on 6 Nov 2026.
Performance Over six months the shares fell 4.9%, against -1.9% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 4.1% over the last twelve months (peer median +4.2%); the operating margin is 9.4% (peer median 11.7%).
Valuation It trades at 18.5× forward earnings against a peer median of 27.7× (5th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.4 points above its cost of capital (5.4% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.83B | CN¥6.42B | CN¥6.44B | CN¥6.65B | CN¥5.93B |
| Revenue growth | — | 0% | -3% | +12% | — |
| Gross profit | CN¥3.93B | CN¥3.27B | CN¥3.27B | CN¥3.72B | CN¥3.37B |
| EBITDA | n/a | CN¥858M | CN¥907M | CN¥1.01B | CN¥966M |
| Net income | CN¥457M | CN¥474M | CN¥622M | CN¥592M | CN¥358M |
| Free cash flow | CN¥1.04B | CN¥830M | CN¥754M | CN¥712M | CN¥892M |
| Capital expenditure | CN¥224M | CN¥147M | CN¥291M | CN¥209M | CN¥292M |
| Total debt | CN¥354M | CN¥506M | CN¥625M | CN¥1.36B | CN¥1.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang CONBA Pharmaceutical 600572.SS | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% |
| By-health 300146.SZ | $2.61B | -1% | +10% | 11% | 25.0× | 5.1% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% |
| Yunnan Baiyao 000538.SZ | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600572.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.9% | +4.8% | 8th lowest of 21 |
| 6-month return | -4.9% | -1.9% | 7th lowest of 20 |
| Distance from 52-week high | -17.6% | -19.8% | 8th highest of 21 |
| Revenue growth (TTM) | +4.1% | +4.2% | 10th highest of 19 |
| Operating margin | 9.4% | 11.7% | 9th lowest of 19 |
| Forward P/E | 18.5× | 27.7× | 5th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | -5.8% | 6.7% | 4th least demanding of 12 |
| Growth delivered (Del g) | +1.9% | +6.8% | 5th lowest of 12 |
| Hurdle (Req g minus delivered) | -7.7 pp | -0.4 pp | 5th least demanding of 12 |
| ROIC minus cost of capital | +4.4 pp | +0.2 pp | 7th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% | +1.9% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | n/a | 49.9% | -13.2% |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | n/a | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 42.9× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | n/a | n/a | n/a |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% | +4.6% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% | +16.6% |